Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Took a strong position in ntek
Marani needs to contact The next Bond Film Producer and feature It's World Class Vodka Martini "Shaken Not Stirred" ...That would be cool.We British love our Vodka.
Expansion on the Brazilian deal is said to be double or even triple according to CEO interview have plan b in place due to huge demand expected as to scale in production opening offices in S.A due to growth Mid Oct commercial up and running exciting times MRIB getting some more...
Don't quite get you Looking at the financials of Mrib You omitted The $40 mil deal in the equation and the expansion. "Past performance does not play here it's future growth"
Call My Broker IB and check it out how you can.
I've shorted many many in my time. No Myth Made more on the down side than upside.
Check with any brokerage when a person shorts a stock if the stocks goes to zero It's all free money he never have to cover . Some do hope that investments never go up (IMO) MRIB case in point.
As an Oxford Grad I'm Pretty sure I command the English Language well ...
As was reported
Marani Brands Ships First Container to Brazil Executing Company's 40 Million Dollar Agreement
http://finance.yahoo.com/news/marani-brands-ships-first-container-131500943.html
could you supply the proof Apple just announce over 10 million IPhone sold since it's release...Mrib said it shipped to Brazil that's good for me Mrib said it's in costco That's good for me...you get the picture I"m buying more of Mrib at these prices come New Year Celebration and Holidays which is know to have the strongest sales for Fine spirits i SAY mrib IS DOING IT RIGHT.
Any idea of the timeline on ad campaign in Brazil? (IMO) we should start to see it when shipments have arrived and stores are being stocked...
MRIB Times the market perfectly huge market share coming from brazil
mark this post 2014 and onward An increase in the consumption of hot beverages such as vodka, cachaça, whiskeys, rum, liqueur, and tequila has been noticed in the country.
http://thebrazilbusiness.com/article/the-beer-wine-and-spirits-industry
Any ideas as to the expansion? my guess we could see 50% or more That'll be $20 mil +++ (IMO) Margrite has approved the first container to be released after receiving the first payment on the mega 40 million dollar agreement. Marani Brands, Inc. looks to ship 2 - 3 containers per month to Brazil with anticipation of expanding the agreement.
Swing this baby weak hands are being flushed out Getting more on the dip Go Mrib
Getting More... (TRUU) with a Buy rating and a $2.20 price target.
Merriman Capital Initiates on True Drinks Holdings, Inc. with a Buy Rating
Merriman Holdings Inc. June 11, 2014 10:03 AM GlobeNewswire Europe
View photo
.
SAN FRANCISCO - June 11, 2014 - Merriman Capital, Inc. ("Merriman"), a wholly owned subsidiary of Merriman Holdings, Inc. (MERR), announced that it has initiated equity research coverage of True Drinks Holdings, Inc. (TRUU) with a Buy rating and a $2.20 price target.
True Drinks develops and markets healthy beverages such as naturally flavored water and energy drinks. The Company`s flagship product, AquaBallTM Naturally Flavored Water, is sugar-free, calorie-free and does not contain harmful sweeteners. AquaBall is a healthy hydration alternative to high sugar drinks for children, and the Company has licensing agreements with Disney and Marvel and distribution to over 28,500 stores nationwide. The current management team brings significant international food and beverage distribution experience. True Drinks was founded in 2008 and is headquartered in Irvine, CA.
True Drinks operates the majority of its sales, R&D and corporate infrastructure through its headquarters in Irvine, California and manufactures the majority of its products at three packing/manufacturing facilities located in New York, California and Texas. TRUU went public through a reverse merger in October of 2012. Since its inception, TRUU has established a distribution presence that encompasses over 26,000 retail storefronts with leading chains such as Albertsons, Kroger, Winn Dixie, H-E-B, Bristol Farms, Gelson`s, WinCo, Sam`s Club and Rite Aid. The company has also forged exclusive branding partnerships with Disney and Marvel, which provide TRUU with a unique marketing opportunity that should ultimately augment customer acquisition rates. TRUU generates revenue through the sale of its AquaBall line to brick-and-mortar retailers and direct-to-consumer sales of AquaBall and Bazi over the internet.
News Huge Deal
True Drinks Announces AquaBall Naturally Flavored Water to Be Available at Wal-Mart Stores in the U.S.
Marketwired
3 hours ago
IRVINE, CA--(Marketwired - September 18, 2014) - True Drinks, Inc. (TRUU), a healthy beverage provider with major entertainment and media company licensing agreements for use of their characters on its proprietary, patented bottles, today announced that their healthy children's drink will be sold in 280 Wal-Mart Stores across the U.S.
True Drinks will now have AquaBall Naturally Flavored water available in the largest retailer in the world, announcing their partnership with Wal-Mart Stores. Both the AquaBall Fruit Punch and Grape 6-packs will be available in stores across the US starting in mid September. This brings another new channel of distribution to AquaBall Naturally Flavored water with the entry to the large volume Mass Merchandiser channel, complimenting the current grocery, c-store, drug, and club business they have developed the past two years.
"Wal-Mart is the pinnacle of retail partnerships, and it speaks to their commitment to providing healthy drink options to children throughout the country as well as the importance of sourcing products made in U.S.," commented Lance Leonard, CEO of True Drinks. "We built this company specifically to change the environment of high sugar drinks marketed toward children. Our partnership with Wal-Mart Stores validates this mission and allows for our brand to be sold at the largest retailer in the world."
Kevin Sherman, CMO True Drinks, added, "This is a time of inflection for True Drinks. We have established business partnerships with the country's largest retailers allowing access to AquaBall to millions of consumers each week. Our ability to capture share within the category and change to status quo will result in a healthier world and reward our company for offering solutions for childhood obesity, juvenile diabetes, and other health related epidemics related to sugary beverages."
About True Drinks, Inc.
True Drinks provides a healthy alternative for kids to drink. Their AquaBallTM is a naturally flavored, vitamin-enhanced, zero-calorie, dye-free, sugar-free alternative to juice and soda. AquaBallTM is currently available in four flavors: orange, grape, fruit punch and berry. Their target consumers are kids, young adults, and their guardians, who are attracted to the product by the entertainment and media characters on the bottle and continue to consume the beverage because of its healthy benefits and great taste. For more information, please visit www.theaquaball.com and www.truedrinks.com. Proudly made in the USA.
About Wal-Mart Stores
Wal-Mart helps people around the world save money and live better -- anytime and anywhere -- in retail stores, online and through their mobile devices. Each week, more than 245 million customers and members visit our nearly 11,000 stores under 71 banners in 27 countries and e-commerce websites in 10 countries. With fiscal year 2014 sales of approximately $473 billion, Wal-Mart employs 2.2 million associates worldwide.
FORWARD-LOOKING STATEMENTS
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "forecast," "intend," "may," "plan," "project," "predict," "if," "should" and "will" and similar expressions as they relate to True Drinks, Inc. are intended to identify such forward-looking statements. True Drinks, Inc. may from time to time update these publicly announced projections, but it is not obligated to do so. Any projections of future results of operations or the anticipated benefits of the merger and other aspects of the proposed merger should not be construed in any manner as a guarantee that such results or other events will in fact occur. These projections are subject to change and could differ materially from final reported results. For a discussion of such risks and uncertainties, see "Risk Factors" in True Drink's report on Form 10-K filed with the Securities and Exchange Commission and its other filings under the Securities Exchange Act of 1934, as amended. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.
Contact:
Investor Relations
True Drinks, Inc.
18552 MacArthur Blvd., Ste. 325
Irvine, CA 92612
ir@truedrinks.com
949-203-3500
Regen had been previously notified by the FDA that it had cleared the clinical trial design, scientific rational and manufacturing components of its IND application.
This is not the fault of bmsn
all other cell base drugs that are being developed by other companies has the same steps to take bmsn is no different.
What's positive is that FDA will guide the process thus ensuring what is needed by them (IMO They will go to FAST TRACT")
Regen will do so .. By leveraging the experience of the FDA and their cell therapy experts,
News BMSN " By closely working with the FDA now, we believe the path for future trials, including other disease indications will be much smoother," said Thomas Ichim, PhD, Chief Scientific Officer of Regen BioPharma Inc.
As I said before This is the new Standard Of the FDA Review of Cell Type Drugs Bmsn is In The System!!!!!!!!!!
According to FDA's new standards to review
This supports why safety issue will pass
"Given the HemaXellerate I(TM) product is derived from the patient's own fat tissue, and numerous key opinion leaders support clinical entry of our product, as demonstrated by our peer reviewed publication http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf., we are confident the safety studies the FDA requested clarification on can be addressed in a timely fashion," stated Thomas Ichim, Regen's Chief Scientific Officer and Board Member.
These key leaders stated "Given the established safety and ease of
autologous SVF administration, it is anticipated that
the proposed procedure will be rapidly adopted by
the market.
Just as a side note current treatment cost ranges into...Current hematopoietic growth factors have several
limitations: their inability to stimulate all hematopoietic
lineages, their inability to heal damaged bone marrow
microenvironment, and their adverse effects associated
with prolonged usage. From a health economics perspective,
these agents are associated with high costs. For example,
according to one report, the cost of treating
neutropenic fever with Neupogen is approximately
$40,000 [46]. This included the cost of drug, hospital
stay, and care of the patient.
Know what you Own.
hey mazo since you have so much info on bmsn could you show the proof of what you state? when did BMSN ever reported revenue as a R&D company and Where is the rejection paper of the ind filed with the FDA? Await your proof of your claims.
The FDA is in infant stage of review of these new treatment such as BMSN's however we can expect word any day the process is a bit different from the old way of review.
FDA approves the first in a new line of cancer-fighting treatments that use patients’ own immune systems against the disease.
The treatment was approved under the FDA’s accelerated approval program, which allows a drug to be sold based on clinical data showing the medicine is reasonable likely to benefit patients.
Before the new drugs, the standard treatment relied on a chemotherapy that had been in use for decades. Drugmakers’ understanding in recent years of the immune system and gene mutations that can be targeted by medicines has led to the proliferation of melanoma treatments, Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a telephone interview.
The FDA is treating BMSN's ind as a new class of drug that may explain the new dept they developed for such and part of the delay in review process that's the system and not the fault of BMSN or RGBP ...thus I doubt it'll be a long time seeing the spotlight is now on fighting cancer with the immune system IMO we will hear very soon from the FDA .
http://mobile.bloomberg.com/news/2014-09-04/merck-wins-u-s-approval-for-melanoma-immunotherapy.html
the world is about to find out
stand Up to cancer is highlighting the science of bmsn check it out on cbs
Stockchaser you've reacted to to rgbp as everyone one did ...when you claim that's Koo's master plan where is the proof you have of THIS MASTER SCHEME" before rgbp was IPO.
any guesses as to the price when hemaxcellerate and dcell vax hits the market?
http://www.fiercepharma.com/story/mercks-melanoma-game-changer-keytruda-likely-bolster-drug-pricing-debate/2014-09-05
Getting close folks New Medicines
This is the sixth drug for melanoma the FDA has approved since 2011. Before the new drugs, the standard treatment relied on a chemotherapy that had been in use for decades. Drugmakers’ understanding in recent years of the immune system and gene mutations that can be targeted by medicines has led to the proliferation of melanoma treatments, Richard Pazdur, director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a telephone interview.
Merck & Co. (MRK) won U.S. approval to bring to market the first in a new line of cancer-fighting treatments that use patients’ own immune systems against the disease.
“It’s an exciting time for our field because of our ability to start harnessing our immune system to attack cancers,
Here'the link an exciting time to be in this field. Bmsn here it comes
http://mobile.bloomberg.com/news/2014-09-04/merck-wins-u-s-approval-for-melanoma-immunotherapy.html
Fda is moving Merk got it's go ahead on first of it's kind cancer treatment Bmsn sooooon
Smart money wants your shares cheap cheap cheap only you can give it to them Know what you own.
Mark this post when lqmt breakout from .29 I'll add more because we're going higher that's my prediction.
You've just confirmed what i'm saying at times there are a flurry of different investors in the marketplace looking to pick up a stock like lqmt and dump all your analysis could not predict that high and the sudden drop in pps because smart money knows that the market is reactionary by FEAR and Greed and they'll play the game if you let them get to your emotions
I disagree that one must look left to know what the market will do ....i can cite so many examples to show this is flawed thinking when a company is moving out of it's current stage as lqmt new money is flowing into it as today's conference will show new investors will move in with different style then as patterns are developed from time to time you can "so call Time the Trade" just look at the spy , DJI , comp, lqmt, new highs will be formed and then levels of support can be established.
Know what you own Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND for Treatment of Drug Resistant Aplastic Anemia
Company Passes Manufacturing and Clinical Reviewers, Clarification of Safety Studies Requested by FDA
SAN DIEGO, CA--(Marketwired - May 12, 2014) - Regen BioPharma Inc., a majority owned subsidiary of Bio-Matrix Scientific Group Inc. (PINKSHEETS: BMSN), announced today an update on its IND # 15376 for use of HemaXellerate I™ in treatment of patients with drug refractory aplastic anemia.
Given that the HemaXellerate I™ possesses the potential to treat multiple conditions, we view the demonstration of safety as a fundamental step, which will position the Company to expand use of this 'stem cell drug' for multiple other indications," noted David Koos, the Company's Chairman & CEO. "Having passed the clinical trial protocol approval and the manufacturing approval, are major milestones for Regen."
sector news
Asiamold debuts the 3D Manufacturing Zone at the 2014 show
Demand for mould nad die solutions remain high for the fast-growing manufacturing markets in China
The 8th edition of Asiamold, Guangzhou International Mould & Die Exhibition will be held at the China Import and Export Fair Complex from 15 – 17 September 2014. Utilising the resources of Messe Frankfurt as well as Euromold, Asiamold 2014 will serve as an influential and professional exhibition for mould and die development in China, highlighting the most up-to-date solutions for China’s increasingly sophisticated manufacturing markets.
Mr Louis Leung, Deputy General Manager, Guangzhou Guangya Messe Frankfurt Co Ltd remarked: “Asiamold continues to be the ideal business platform for the mould and die industry. For the past couple of years, thematic zones have become the key component to the show’s success, helping top manufacturing industry professionals with their sourcing needs. And for 2014, we have added the new 3D Manufacturing Zone to highlight this revolutionary service in the mould and die-casting industry.”
Widely known for its ability to cut down research and development time and costs for specific as well as precision components, 3D printing within China’s mould and die industry is growing at an exponential rate. With the help of advanced product development software, 3D printing technology has become a key component, particularly for mould design. This technology is especially apparent within the automotive, aerospace, industrial and medical fields. By 2021, the 3D printing market is expected to be worth USD 10.8 billion, creating ample business opportunities for industry players.
For 2014, prominent 3D exhibitors have already confirmed their intention to present a unique selection of solutions and innovative products at the 3D Manufacturing Zone. Some of these companies include Beijing TierTime, FARO Technologies, Tianjin Vision Sensitive Technology, Hangzhou Shining 3D Tech, Shenzhen Esun, Guangzhou Seal Laser Rapid Prototype, and Shenzhen 3D Printing Technology.
In addition to the newly-added 3D manufacturing zone, thematic zones scheduled for the 2014 show also include:
Plastic Engineering and Raw Material
Automold & Engineering
Foundry & Die-casting
Asiametal
Asiabearing
Demand for mould and die solutions remain high for the fast-growing manufacturing markets in China
Renowned for its manufacturing capacity, the Chinese marketplace for mould and die producers remains highly profitable for domestic and international suppliers. The country’s demand for mould and die solutions, which in 2013 was collectively worth USD 70 billion, are driven primarily by the country’s manufacturing sector. While the domestic mould and die market is strongly supported by local suppliers, the demand for higher quality as well as imported moulding solutions and technology from overseas countries continue to rise.
In the first six months of 2013, China’s value of imported mould and die-casted products was worth USD 1.22 billion, a 4.9% increase from 2012. With manufacturing being one of the main economic pillars in China, it is crucial for local manufacturing firms to continuously source for improved mould making technologies and solutions to aid their overall manufacturing growth. Currently, overseas mould and die products and solutions are primarily ordered from countries and regions including Canada, Denmark, France, Germany, Italy, Japan, South Korea, Singapore, Taiwan and the US. For brands looking to sell to the China market, Asiamold remains a top choice for meeting targeted and qualified buyers.
Asiamold is organised by Guangzhou Guangya Messe Frankfurt in cooperation with EuroMold, the Hong Kong Federation of Innovative Technologies and Manufacturing Industries Limited and Guangzhou Die & Mould Industry Association. The show is also a part of an alliance with member shows in Africa (AfriMold), Asia (INTERMOLD Japan, INTERMOLD Korea), Europe (Euromold, RosMould) and the Americas (AmeriMold).
For more information, visit www.asiamold-china.com, or
email asiamoldatchina.messefrankfurt.com.
-end-
Background information on Messe Frankfurt
Messe Frankfurt is one of the world’s leading trade show organisers with around 543* million euros in sales and 2,026* active employees worldwide. The Messe Frankfurt Group has a global network of 28 subsidiaries and approx. 50 international Sales Partners, giving it a presence for its customers in more than 150 countries. Events "made by Messe Frankfurt” take place at more than 30 locations around the globe. In 2013, Messe Frankfurt organised 114* trade fairs, of which more than half took place outside Germany.
Messe Frankfurt’s exhibition grounds, featuring 578,000 square metres, are currently home to ten exhibition halls and an adjacent Congress Center. The company is publicly owned, with the City of Frankfurt holding 60 percent and the State of Hesse 40 percent.
For more information, please visit our website at: www.messefrankfurt.com.
*Preliminary figures (for 2013)
[0070] 3D printing may be used to produce parts directly from computer-generated design data. 3D printing uses layering techniques to build three-dimensional parts. Such parts may be formed by forming successive thin cross-sections of the desired part. The individual cross-sections are formed by bonding together adjacent grains of a granular material on a generally planar surface of a bed of the granular material. Each layer is bonded to a previously formed layer to form the desired three-dimensional article at the same time as the grains of each layer are bonded together. 3D printing can be quicker and less expensive than machining of prototype parts or production of cast or molded parts by conventional "hard" or "soft" tooling techniques, that can take from a few weeks to several months, depending on the complexity of the part.
[0071] 3D printing may be useful in design-related fields for visualization, demonstration, and mechanical prototyping. It may also be useful for making patterns for molding processes. 3D printing techniques may be further useful, for example, in the fields of medicine and dentistry, where expected outcomes may be modeled prior to performing procedures. Other fields that may benefit from rapid prototyping technology include architectural designing, as well as others in which visualization of a design is useful.
[0072] One application of 3D printing is production of parts such as enclosures for consumer electronics. Parts for consumer electronics may have small sizes, tight constraints on their dimensions and complex shapes, which can make traditional subtractive manufacturing method difficult or expensive.
[0073] Another application of 3D printing is in the medical field. For example, replacement human body parts such as artificial bones may be created with 3D printing. Other examples may include scaffolds for tissue engineering, including but not limited to scaffolds that facilitate cell attachment and migration, delivery and retention of cells and biochemical factors, delivery and diffusion of cell nutrients and cell-expressed products, etc.
[0074] Yet another application of 3D printing is in the field of individualized consumer goods. For example, 3D printing can be used to create individualized interfaces to human body, such as customized ergonomic handles that fit each individual's hands.
* * * * *